Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) will announce its financial results for Q2 2020 on August 6, 2020, post-market. A conference call is scheduled for 5:30 PM ET to discuss these results. The company focuses on women's health, particularly in breast aesthetics and reconstruction, with a product range including the Motiva Implants® and the Divina® 3D Simulation System. Motiva Implants® have received FDA approval and are available in over 80 countries through various distribution channels.